Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis

Expert Opinion on Drug Safety

Volumn 12, Issue 4, 2013, Pages 545-557

  Scheen, Andre ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

DPP 4 inhibitor; Gliptin; Glucagon like peptide 1; Pancreatitis; Pharmacovigilance; Type 2 diabetes mellitus

Indexed keywords

ALOGLIPTIN; EXENDIN 4; LINAGLIPTIN; METFORMIN; SAXAGLIPTIN; SITAGLIPTIN; TETRAHYDROLIPSTATIN; VILDAGLIPTIN;

ACUTE PANCREATITIS; ALCOHOL CONSUMPTION; COHORT ANALYSIS; DIABETIC PATIENT; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; POSTMARKETING SURVEILLANCE; REVIEW; RISK FACTOR;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; PANCREATITIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK;

EID: 84878616155     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2013.793671     Document Type: Review

References (86)

1. DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-95
2. Scheen AJ. A review of gliptins in 2011. Expert Opin Pharmacother 2012;13:81-99
3. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-705 (Pubitemid 46048557)
4. Scheen AJ. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. Diabetes Metab 2012;38:89-101
5. Scheen AJ. Cardiovascular effects of gliptins. Nat Rev Cardiol 2013;10:73-84
6. Scheen AJ. Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease. Expert Opin Drug Metab Toxicol 2013;published on line 2013/03/07; doi: 10.1517/17425255.2013.777428
7. Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 2010;12:648-58
8. Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs 2011;71:1441-67
9. Dhillon S. Sitagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 2010;70:489-512
10. Keating GM. Vildagliptin: a review of its use in type 2 diabetes mellitus. Drugs 2010;70:2089-112
11. Yang LP. Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU. Drugs 2012;72:229-48
12. Scott LJ. Alogliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 2010;70:2051-72
13. Scott LJ. Linagliptin: in type 2 diabetes mellitus. Drugs 2011;71:611-24
14. Goo-en K, Gräber S. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab 2012;published on line; doi: 10.1111/j.1463-1326.2012.01610.x
15. Mikhail N. Safety of dipeptidyl peptidase 4 inhibitors for treatment of type 2 diabetes. Curr Drug Safety 2011;6:304-9
16. Richard KR, Shelburne JS, Kirk JK. Tolerability of dipeptidyl peptidase-4 inhibitors: a review. Clin Ther 2011;33:1609-29
17. Butler PC, Matveyenko AV, Dry S, et al. Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire? Diabetologia 2010;53:1-6
18. Anderson SL, Trujillo JM. Association of pancreatitis with glucagon-like peptide-1 agonist use. Ann Pharmacother 2010;44:904-9
19. Alves C, Batel-Marques F, Macedo AF. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Res Clin Pract 2012;98:271-84
20. Morales J. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors. Postgrad Med 2011;123:189-201
21. Scheen AJ. Dipeptidylpeptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor agonists: yes. Eur J Intern Med 2012;23:126-31
22. Madsbad S. Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) agonists: no. Eur J Intern Med 2012;23:132-6
23. Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008;CD006739
24. Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011;141:150-6
25. Doyle ME, Egan JM. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 2007;113:546-93 (Pubitemid 46365961)
26. Butler PC, Dry S, Elashoff R. GLP-1-based therapy for diabetes: what you do not know can hurt you. Diabetes Care 2010;33:453-5
27. Noel RA, Braun DK, Patterson RE, et al. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 2009;32:834-8
28. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010;33:2349-54
29. Girman CJ, Kou TD, Cai B, et al. Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes. Diabetes Obes Metab 2010;12:766-71
30. Gonzalez-Perez A, Schlienger RG, Rodriguez LA. Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a population-based cohort study. Diabetes Care 2010;33:2580-5
31. Lai SW, Muo CH, Liao KF, et al. Risk of acute pancreatitis in type 2 diabetes and risk reduction on anti-diabetic drugs: a population-based cohort study in Taiwan. Am J Gastroenterol 2011;106:1697-704
32. Shen HN, Chang YH, Chen HF, et al. Increased risk of severe acute pancreatitis in patients with diabetes. Diabet Med 2012;29:1419-24
33. Yang L, He Z, Tang X, et al. Type 2 diabetes mellitus and the risk of acute pancreatitis: a meta-analysis. Eur J Gastroenterol Hepatol 2013;25:225-31
34. Bhanot UK, Moller P. Mechanisms of parenchymal injury and signaling pathways in ectatic ducts of chronic pancreatitis: implications for pancreatic carcinogenesis. Lab Invest 2009;89:489-97
35. Brodovicz KG, Kou TD, Alexander CM, et al. Impact of diabetes duration and chronic pancreatitis on the association between type 2 diabetes and pancreatic cancer risk. Diabetes Obes Metab 2012;doi: 10.1111/j.1463-1326.2012. 01667.x
36. Gale EA. GLP-1-based therapies and the exocrine pancreas: more light, or just more heat? Diabetes 2012;61:986-8
37. Butler AE, Campbell-Thompson M, Gurlo T, et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;published on line 2013/03/26; doi: 10.2337/db12-1686
38. Gier B, Matveyenko AV, Kirakossian D, et al. Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras (G12D) mouse model. Diabetes 2012;61:1250-62
39. Nyborg NC, Molck AM, Madsen LW, et al. The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species. Diabetes 2012;61:1243-9
40. Matveyenko AV, Dry S, Cox HI, et al. Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes 2009;58:1604-15
41. Engel SS, Williams-Herman DE, Golm GT, et al. Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract 2010;64:984-90
42. Koehler JA, Baggio LL, Lamont BJ, et al. Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes 2009;58:2148-61
43. Busch SJ, Hoffmann P, Sahota P, et al. Studies in rodents with the dipeptidyl peptidase-4 inhibitor vildagliptin to evaluate possible drug-induced pancreatic histological changes that are predictive of pancreatitis and cancer development in man. Diabetes Obes Metab 2013;15:72-6
44. Garg R, Hussey C, Ibrahim S. Pancreatitis associated with the use of sitagliptin and orlistat combination: a case report. Diabet Med 2010;27:485-6
45. Iyer SN, Drake AJ III, West RL, et al. Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide. Endocr Pract 2012;18:e10-13
46. Sue M, Yoshihara A, Kuboki K, et al. A case of severe acute necrotizing pancreatitis after administration of sitagliptin. Clin Med Insights Case Rep 2013;6:23-7
47. Girgis CM, Champion BL. Vildagliptin-induced acute pancreatitis. Endocr Pract 2011;17:e48-50
48. Nakata H, Sugitani S, Yamaji S, et al. Pancreatitis with pancreatic tail swelling associated with incretin-based therapies detected radiologically in two cases of diabetic patients with end-stage renal disease. Intern Med 2012;51:3045-9
49. Kunjathaya P, Ramaswami PK, Krishnamurthy AN, et al. Acute necrotizing pancreatitis associated with vildagliptin. J Pancreas 2013;14:81-4
50. Administration UFaD. Sitagliptin (marketed as Januvia and Janumet): reports of acute pancreatitis. http US Food and Drug Administration (2009) Information for healthcare professionals-acute pancreatitis and sitagliptin (marketed as Januvia and Janumet). Available from: http://wwwfdagov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationfor PatientsandProviders/DrugSafety InformationforH://wwwfdagov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm183800htm Accessed 30 June 2012]
51. Spranger J, Gundert-Remy U, Stammschulte T. GLP-1-based therapies: the dilemma of uncertainty. Gastroenterology 2011;141:20-3
52. Olansky L. Do incretin-based therapies cause acute pancreatitis? J Diabetes Sci Technol 2010;4:228-9
53. Raschi E, Piccinni C, Poluzzi E, et al. The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. Acta Diabetol 2011;published on line 2011/10/20; doi: 10.1007/s00592-011-0340-7
54. Pariente A, Gregoire F, Fourrier-Reglat A, et al. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf 2007;30:891-8 (Pubitemid 47481444)
55. Monami M, Dicembrini I, Martelli D, et al. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin 2011;27(Suppl 3):57-64
56. Williams-Herman D, Engel SS, Round E, et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord 2010;10:7
57. Ligueros-Saylan M, Foley JE, Schweizer A, et al. An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials. Diabetes Obes Metab 2010;12:495-509
58. Karyekar C, Donovan M, Allen E, et al. Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes. Postgrad Med 2011;123:63-70
59. Gerrald KR, Van Scoyoc E, Wines RC, et al. Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 2012;14:481-92
60. Doucet J, Chacra A, Maheux P, et al. Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus. Curr Med Res Opin 2011;27:863-9
61. Company Bristol-MyersSquibb. Saxagliptin. Data on file SAXA052. Princeton, NJ, USA
62. Rendell M, Drincic A, Andukuri R. Alogliptin benzoate for the treatment of type 2 diabetes. Expert Opin Pharmacother 2012;13:553-63
63. Pratley RE, McCall T, Fleck PR, et al. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies. J Am Geriatr Soc 2009;57:2011-19
64. Berhan A, Berhan Y. Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studies. BMC Endocr Disord 2013;13:9
65. Schernthaner G, Barnett AH, Emser A, et al. Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus. Diabetes Obes Metab 2012;14:470-8
66. Del Prato S, Taskinen MR, Owens DR, et al. Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: pooled analysis of data from three placebo-controlled phase III trials. J Diabetes Complications 2013;published on line 2013/02/14; doi: 10.1016/j.jdiacomp.2012.11.008
67. Lando HM, Alattar M, Dua AP. Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase- 4 inhibitors in the outpatient setting. Endocr Pract 2012;18:472-7
68. Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009;25:1019-27
69. Singh S, Chang HY, Richards TM, et al. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA 2013;published on line 2013/02/27; doi: 10.1001/jamainternmed.2013.2720:1-6
70. Gale EA. GLP-1 based agents and acute pancreatitis. BMJ 2013;346:f1263
71. Gier B, Butler PC. Glucagonlike peptide 1-based drugs and Pancreatitis: clarity at last, but what about pancreatic cancer?: comment on "Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus". JAMA 2013;published on line 2013/03/07; doi: 10.1001/jamainternmed.2013.3374:1-3
72. Food and Drug Administration. FDA drug safety communication: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes. Available from: wwwfdagov/Drugs/DrugSafety/ucm343187htm 2013
73. Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA 1999;281:824-9 (Pubitemid 29113743)
74. Gale EA. Collateral damage: the conundrum of drug safety. Diabetologia 2009;52:1975-82
75. Dore DD, Bloomgren GL, Wenten M, et al. A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab 2011;13:559-66
76. Romley JA, Goldman DP, Solomon M, et al. Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population. Diabetes Technol Ther 2012;14:904-11
77. Wenten M, Gaebler JA, Hussein M, et al. Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study. Diabet Med 2012;29:1412-18
78. Franks AS, Lee PH, George CM. Pancreatitis: a potential complication of liraglutide? Ann Pharmacother 2012;46:1547-53
79. Aroda VR, Ratner R. The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review. Diabetes Metab Res Rev 2011;27:528-42
80. Gallwitz B. Benefit-risk assessment of exenatide in the therapy of type 2 diabetes mellitus. Drug Saf 2010;33:87-100
81. Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide-the FDA's review of a new antidiabetic therapy. N Engl J Med 2010;362:774-7
82. Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. Arch Intern Med 2005;165:1363-9 (Pubitemid 40973418)
83. Zhang Q, Rajagopalan S, Mavros P, et al. Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database. Curr Med Res Opin 2010;26:1697-703
84. Drucker DJ, Sherman SI, Bergenstal RM, et al. The safety of incretin-based therapies-review of the scientific evidence. J Clin Endocrinol Metab 2011;96:2027-31
85. Labuzek K, Kozlowski M, Szkudlapski D, et al. Incretin-based therapies in the treatment of type 2 diabetes-more than meets the eye? Eur J Intern Med 2013;24:207-12
86. Scheen AJ. Exenatide once weekly in type 2 diabetes. Lancet 2008;372:1197-8